<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00119067</url>
  </required_header>
  <id_info>
    <org_study_id>CDC-NCID-3344</org_study_id>
    <nct_id>NCT00119067</nct_id>
  </id_info>
  <brief_title>CDC Anthrax Vaccine Clinical Trial</brief_title>
  <official_title>Anthrax Vaccine Adsorbed: Human Reactogenicity and Immunogenicity Trial to Address Change in Route of Administration and Dose Reduction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centers for Disease Control and Prevention</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Walter Reed Army Institute of Research (WRAIR)</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>Baylor College of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centers for Disease Control and Prevention</source>
  <brief_summary>
    <textblock>
      Anthrax Clinical Trial Objectives:&#xD;
&#xD;
      To assess whether:&#xD;
&#xD;
        -  Anthrax vaccine (AVA or BioThrax, BioPort Corp. Lansing MI) administered by the&#xD;
           intramuscular (IM) route elicits antibody responses that are not inferior (i.e.,&#xD;
           &quot;non-inferior&quot;) to that achieved by the currently licensed schedule.&#xD;
&#xD;
        -  BioThrax administered by the IM route and containing fewer numbers of doses elicits&#xD;
           antibody responses that are not inferior (i.e., &quot;non-inferior&quot;) to that achieved by the&#xD;
           currently licensed schedule.&#xD;
&#xD;
        -  Differences in reactogenicity exist between the IM and subcutaneous (SQ) administration&#xD;
           of BioThrax.&#xD;
&#xD;
      Additionally for the final report we will assess whether:&#xD;
&#xD;
        -  Occurrence of adverse events following AVA administration is influenced by selected risk&#xD;
           factors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a 43-month prospective, randomized, double-blind, placebo-controlled comparison&#xD;
      of immunogenicity and reactogenicity elicited by BioThrax given by different routes of&#xD;
      administration (SQ versus IM) and dosing regimens (as many as 8 doses versus as few as 4&#xD;
      doses). Sterile saline is used as the placebo where doses are dropped in regimens using AVA,&#xD;
      and in the all-placebo study group.&#xD;
&#xD;
      This study is conducted among a total of 1564 healthy adult men and women (18 to 61 years of&#xD;
      age) at five sites in the United States. Participants were randomized into one of 6 study&#xD;
      groups with 260 participants per group. One group receives BioThrax given as currently&#xD;
      licensed (SQ with 6 doses followed by annual boosters); another group is given placebo IM&#xD;
      (130 participants) or SQ (130 participants) in the currently licensed dosing regimen. The&#xD;
      four other groups receive BioThrax IM in modified dosing regimens; placebo is given when a&#xD;
      dose of BioThrax is omitted from the licensed dosing regimen. There are a total of 25&#xD;
      required visits for this study, during which all participants receive an injection of vaccine&#xD;
      or placebo (8 injections total), have a blood sample drawn (16 or 17 total), and have an&#xD;
      in-clinic examination for adverse events (22 total).&#xD;
&#xD;
      Immunogenicity is assessed by assaying 16 serial blood samples obtained from all participants&#xD;
      and a 17th sample from a subset of participants before vaccination and at other specified&#xD;
      times. Total anti-protective antigen IgG antibody (anti-PA IgG) is quantified using a&#xD;
      standardized and validated enzyme-linked immunosorbent assay (ELISA); the primary study&#xD;
      endpoints are 4-fold rise in antibody titer and antibody concentration relative to the&#xD;
      pre-vaccination titers or assay reactivity threshold. A subset of serum samples is also&#xD;
      assayed in an in vitro toxin neutralization assay (TNA) to measure the functional activity of&#xD;
      anti-BioThrax antibodies. The kinetics of the immune response to BioThrax are examined at 3&#xD;
      time points in the study and blood samples from a subset of participants will be further&#xD;
      tested in correlates of protection and immunogenetics substudies. All adverse events (AEs),&#xD;
      including vaccine reactogenicity, are actively monitored. While all AEs will be ascertained&#xD;
      among study participants, several endpoints will be defined based on the likelihood of their&#xD;
      occurrence and/or their clinical importance. Of primary interest is the occurrence of local&#xD;
      AEs such as warmth, tenderness, itching, pain, arm motion limitation, erythema, induration,&#xD;
      nodule, and bruise. Systemic AEs such as fever, fatigue, muscle ache, headache, temperature,&#xD;
      and painful axillary adenopathy are also evaluated.&#xD;
&#xD;
      This study is expected to provide the basis for consideration of change in route of BioThrax&#xD;
      administration from SQ to IM and reduction in number of vaccine doses required for primary&#xD;
      and booster immunization.&#xD;
&#xD;
      There is an interim analysis of data collected through each participant's first 7 months of&#xD;
      this study for consideration in changing the route of BioThrax administration from SQ to IM,&#xD;
      and elimination of the 2 week vaccine priming dose.&#xD;
&#xD;
      At the end of the study, the Sponsor will present the entire results of the trial to FDA for&#xD;
      consideration in elimination of additional doses from the licensed BioThrax schedule. At that&#xD;
      time, the Sponsor will also supplement these data with results from parallel non-human&#xD;
      primate challenge studies and additional research on immunologic correlates of protection.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2002</start_date>
  <completion_date type="Actual">February 2010</completion_date>
  <primary_completion_date type="Actual">February 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>local AEs - warmth, tenderness, itching, pain, arm motion limitation, erythema, induration, nodule, and bruise</measure>
    <time_frame>completed</time_frame>
    <description>no safety issues to assessing this</description>
  </primary_outcome>
  <primary_outcome>
    <measure>systemic AEs -fever, fatigue, muscle ache, headache, temperature, and painful axillary adenopathy</measure>
    <time_frame>completed</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>non-inferiority of anti-protective antigen IgG geometric mean concentration (GMC) of the study groups (8-SQ, 7-IM, 5-IM, 4-IM) to the 8-SQ group</measure>
    <time_frame>completed</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>A subset (30%) samples are selected for toxin neutralization assay</measure>
    <time_frame>completed</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the kinetics of the immune response to BioThrax are examined at 3 time points in the study</measure>
    <time_frame>completed</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>assessment of other immune humoral and cell mediated antibody responses</measure>
    <time_frame>ongoing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>assessment of risk factors for adverse events</measure>
    <time_frame>ongoing</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">1560</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>AVA 8-SQ</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>receive 8 injections of AVA SQ</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AVA 8-IM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>receive 8 injections of AVA IM</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AVA 7-IM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>receive 7 injections of AVA IM</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AVA 5-IM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>receive 5 injections of AVA IM</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AVA 4-IM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>receive 4 injections of AVA IM; months 0, 2, 6 and a booster at month 42</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline placebo IM or SQ</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BioThrax or Anthrax Vaccine Adsorbed</intervention_name>
    <arm_group_label>AVA 4-IM</arm_group_label>
    <arm_group_label>AVA 5-IM</arm_group_label>
    <arm_group_label>AVA 7-IM</arm_group_label>
    <arm_group_label>AVA 8-IM</arm_group_label>
    <arm_group_label>AVA 8-SQ</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Read and signed the Informed Consent Document&#xD;
&#xD;
          -  Female or male, 18 to 61 years old (up to 62nd birthday)&#xD;
&#xD;
          -  Females must agree to exercise adequate birth control from the time of the screening&#xD;
             procedures to one month after the last vaccination&#xD;
&#xD;
          -  Willingness and ability to return for all follow-up visits and blood collections for&#xD;
             the duration of the study&#xD;
&#xD;
          -  Ability to understand and comply with planned study procedures&#xD;
&#xD;
          -  Agree to complete the Participant Diary (Appendix G) and to report concomitant&#xD;
             medications and AEs during the study period&#xD;
&#xD;
          -  Have two intact upper arms with sufficient subcutaneous and intramuscular tissue in&#xD;
             the deltoid regions for vaccine administration.&#xD;
&#xD;
          -  Potential participants with a history of the following conditions remain eligible for&#xD;
             study enrollment: gestational diabetes; treated, controlled, uncomplicated&#xD;
             hypertension; treated hypo- or hyperthyroidism; cured nonmetastatic cancer;&#xD;
             disease-free for 5 years (excluding hematologic malignancies); localized skin cancer,&#xD;
             resected (including squamous cell and basal cell carcinomas, participants with a&#xD;
             history of melanoma must be disease-free for 5 years); exercise-induced bronchospasm;&#xD;
             mild asthma: use of inhalers only for control of symptoms is acceptable (Persons who&#xD;
             have required hospitalization for asthma within the previous 2 years or those who&#xD;
             require chronic or frequent oral/parenteral steroids will not be eligible; use of low&#xD;
             to medium doses of inhaled steroids; history of coronary artery disease, asymptomatic&#xD;
             (NYHA Function Class I), on a stable medical regimen. Persons meeting these criteria&#xD;
             must be at least 2 years post-myocardial infarction, cardiac bypass surgery, and/or&#xD;
             percutaneous coronary intervention (e.g., angioplasty, stent placement, etc) in order&#xD;
             to qualify. Persons with a history of cardiac disease must be under the care of a&#xD;
             physician.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior history of anthrax or immunization against anthrax&#xD;
&#xD;
          -  Known allergy to aluminum hydroxide, formaldehyde, benzethonium chloride, or latex&#xD;
&#xD;
          -  Pregnancy or plans to become pregnant for the duration of the study and/or not&#xD;
             agreeing to exercise adequate birth control from the time of the screening procedures&#xD;
             to one month after the last vaccination&#xD;
&#xD;
          -  Received experimental products within 30 days prior to study entry&#xD;
&#xD;
          -  Plans to receive experimental products within 60 days after study entry&#xD;
&#xD;
          -  Received a live vaccine outside this trial within 30 days prior to study entry&#xD;
&#xD;
          -  Received an inactivated vaccine outside this trial within 14 days prior to study entry&#xD;
&#xD;
          -  Plans to receive a live vaccine outside this trial within 60 days after study entry&#xD;
&#xD;
          -  Plans to receive an inactivated vaccine outside this trial within 42 days after study&#xD;
             entry&#xD;
&#xD;
          -  Received immunosuppressive therapy within 30 days prior to study entry&#xD;
&#xD;
          -  Plans to receive immunosuppressive therapy within 60 days after study entry&#xD;
&#xD;
          -  Use of cytotoxic therapy in the previous 5 years&#xD;
&#xD;
          -  Plans to receive cytotoxic therapy within 60 days after study entry&#xD;
&#xD;
          -  Receipt of parenteral immunoglobulin or blood products within three months of study&#xD;
&#xD;
          -  Plans to receive parenteral immunoglobulin or blood products within 60 days after&#xD;
             study entry&#xD;
&#xD;
          -  Active malignancy or history of metastatic or hematologic malignancy&#xD;
&#xD;
          -  Any current diabetes&#xD;
&#xD;
          -  Cardiovascular disease with a significant likelihood of progression over 5 years,&#xD;
             including any person with a history of cardiomyopathy or congestive heart failure&#xD;
&#xD;
          -  Moderate to severe asthma, chronic obstructive pulmonary disease, other significant&#xD;
             pulmonary disease&#xD;
&#xD;
          -  Persons who are using high doses of inhaled steroids&#xD;
&#xD;
          -  Clinically recognized hepatic or renal insufficiency&#xD;
&#xD;
          -  Inflammatory, vasculitic, or rheumatic disease including systemic lupus erythematosis,&#xD;
             polymyalgia rheumatica and rheumatoid arthritis, scleroderma&#xD;
&#xD;
          -  Known HIV, hepatitis B or hepatitis C infection&#xD;
&#xD;
          -  Other conditions known to produce or be associated with immune suppression&#xD;
&#xD;
          -  Neuropathy or other evolving neurologic condition&#xD;
&#xD;
          -  Unstable and/or moderate to severe mental illness&#xD;
&#xD;
          -  Ongoing drug abuse/dependence (including alcohol)&#xD;
&#xD;
          -  Seizure disorder&#xD;
&#xD;
          -  In addition to the conditions listed above, moderate or severe illness and/or oral&#xD;
             temperature higher than 100.4ËšF within 3 days of injection or chronic condition that,&#xD;
             in the opinion of the investigator, would render injection unsafe or would interfere&#xD;
             with evaluations would be considered a temporary exclusion criterion.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>61 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jennifer Wright, DVM</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centers for Disease Control and Prevention</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dr Scott Parker</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Harry Keyserling</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr Janiine Babcock</name>
      <address>
        <city>Silver Spring</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Gregory Poland</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Wendy Keitel</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <study_first_submitted>July 6, 2005</study_first_submitted>
  <study_first_submitted_qc>July 11, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 13, 2005</study_first_posted>
  <last_update_submitted>February 25, 2014</last_update_submitted>
  <last_update_submitted_qc>February 25, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 26, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Anthrax</keyword>
  <keyword>Vaccine</keyword>
  <keyword>Immunogenicity</keyword>
  <keyword>Reactogenicity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anthrax</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>December 9, 2014</submitted>
    <returned>January 5, 2015</returned>
    <submitted>July 28, 2015</submitted>
    <returned>August 20, 2015</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

